论文部分内容阅读
检测了１２例活动期ＳＬＥ病人皮质类固醇治疗前后血清中可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）及培养上清中ＩＬ－２的水平，并检测了其中９例病人血清Ｉ－Ｌ６水平。治疗前ＩＬ－２水平为１０．９±６．０Ｕ／ｍｌ，明显低于正常对照组（３８．３±１８．８Ｕ／ｍｌ），ｓＩＬ－２Ｒ水平为７０８±３６７Ｕ／ｍｌ，明显高于正常对照组（２１１±１３７Ｕ／ｍｌ），ＩＬ－６水平为７５．９±４２．５Ｕ／ｍ１，明显高于正常对照组（２１．３±５．８Ｕ／ｍｌ）。皮质类固醇治疗１～６个月后，ＩＬ－２，ｓＩＬ－２Ｒ及ＩＬ－６水平分别为３２．５±２５．６Ｕ／ｍｌ，３５２±１２０Ｕ／ｍｌ及５８±１９．３Ｕ／ｍｌ，均随着临床症状的好转而趋于正常。我们认为ＩＬ－２，ｓＩＬ－２Ｒ的检测可作为监测ＳＬＥ病情活动性的指标。ＩＬ－６的检测在ＳＬＥ病人中亦有一定意义。
Serum levels of soluble interleukin 2 receptor (sIL-2R) and IL-2 in culture supernatants were measured before and after corticosteroid treatment in 12 active SLE patients. Serum levels of I-L6 were measured in 9 patients. The level of IL-2 before treatment was 10.9 ± 6.0U / ml, which was significantly lower than that of the normal control group (38.3 ± 18.8U / ml) and the level of sIL-2R was 708 ± 367U / ml, which was significantly higher than the normal The level of IL-6 in the control group (211 ± 137U / ml) was 75.9 ± 42.5U / ml, which was significantly higher than that in the normal control group (21.3 ± 5.8U / ml). Levels of IL-2, sIL-2R and IL-6 were 32.5 ± 25.6U / ml, 352 ± 120U / ml and 58 ± 19.3U / ml, respectively, in 1 to 6 months after corticosteroid treatment The clinical symptoms turn to normal. We believe that the detection of IL-2, sIL-2R can be used as an indicator of SLE activity. The detection of IL-6 also has some significance in SLE patients.